Dupilumab for eczema

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 7 registered trials.

Why this status

  1. 20 Mar 2015: Trial registered, NCT02395133
  2. 25 Mar 2015: Trial started, NCT02395133
  3. 15 Feb 2017: Trial registered, NCT03054428
  4. 21 Mar 2017: Trial started, NCT03054428
  5. 26 Sep 2017: Trial registered, NCT03293030
  6. 12 Sep 2018: Trial registered, NCT03667014
  7. 22 Oct 2018: Trial started, NCT03293030
  8. 1 Nov 2018: Trial started, NCT03667014

The trials

NCT01859988: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

State
Completed
Phase
Phase 2
People
380 taking part
Started
May 2013
Primary completion
May 2014
Arms
Dupilumab 300 mg qw
Results
Posted on the registry
Papers
doi:10.1001/jamadermatol.2022.6192, doi:10.1016/j.jaad.2015.10.043, doi:10.1016/j.jaad.2016.04.054, doi:10.1016/s0140-6736(15)00388-8, doi:10.1097/der.0000000000000698, doi:10.1111/cts.13363
  1. 22 May 2013: Trial registered
  2. 28 Aug 2017: Trial results posted

NCT02395133: A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

State
Completed
Phase
Phase 3
People
422 taking part
Started
25 Mar 2015
Primary completion
Jul 2016
Arms
Dupilumab 300 mg Q8W, Dupilumab 300 mg Q4W, Dupilumab 300 mg Q2W/QW
Results
Posted on the registry
Papers
doi:10.1001/jamadermatol.2019.3617, doi:10.1007/s12325-025-03124-8, doi:10.3389/fimmu.2024.1466372
  1. 20 Mar 2015: Trial registered
  2. 25 Mar 2015: Trial started
  3. 18 Oct 2016: Trial completed
  4. 17 Oct 2018: Trial results posted

NCT03054428: Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

State
Completed
Phase
Phase 3
People
251 taking part
Started
21 Mar 2017
Primary completion
4 Apr 2018
Arms
Dupilumab 300 mg Q4W, Dupilumab 200 mg or 300 mg Q2W
Results
Posted on the registry
Papers
doi:10.1001/jamadermatol.2019.3336, doi:10.1001/jamadermatol.2022.6192, doi:10.1002/cpt.2366, doi:10.1007/s13555-019-00333-2, doi:10.1007/s13555-021-00568-y, doi:10.1007/s40257-019-00478-y, doi:10.1007/s40257-020-00577-1, doi:10.1007/s40257-020-00583-3, doi:10.1007/s40257-022-00683-2, doi:10.1007/s40257-025-00952-w, doi:10.1016/j.jaad.2020.02.060, doi:10.1111/bjd.18476, doi:10.3389/fimmu.2024.1466372
  1. 15 Feb 2017: Trial registered
  2. 21 Mar 2017: Trial started
  3. 5 Jun 2018: Trial completed
  4. 23 Jul 2019: Trial results posted

NCT03293030: Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

State
Completed
Phase
Phase 4
People
17 taking part
Started
22 Oct 2018
Primary completion
23 Feb 2023
Arms
Dupilumab treatment
Results
Posted on the registry
  1. 26 Sep 2017: Trial registered
  2. 22 Oct 2018: Trial started
  3. 23 Feb 2023: Trial completed
  4. 14 Nov 2025: Trial results posted

NCT03667014: The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

State
Completed
Phase
Phase 4
People
34 taking part
Started
1 Nov 2018
Primary completion
15 Dec 2022
Arms
Dupilumab treatment
Results
Posted on the registry
Papers
PMID 42027418
  1. 12 Sep 2018: Trial registered
  2. 1 Nov 2018: Trial started
  3. 15 Dec 2022: Trial completed
  4. 9 Jan 2024: Trial results posted

NCT04520308: An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis

State
State not given
Phase
Phase 4
People
45 planned
Started
1 Sep 2020
Primary completion
26 Feb 2021
Arms
dupilumab
Results
None posted
  1. 20 Aug 2020: Trial registered

NCT07187089: Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab

State
Withdrawn before it started
Phase
Phase 4
People
0 taking part
Started
11 Nov 2025
Primary completion
23 Dec 2027
Arms
dupilumab
Results
None posted
  1. 22 Sep 2025: Trial registered
  2. 28 Nov 2025: Trial withdrawn

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Dupixent, Dupilumab (SAR231893), Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose, Dupilumab Only Product, Dupilumab SAR231893, Dupilumab step-down, Dupilumab therapy, REGN3500 + Dupilumab Combo, Vanicream- Experienced Dupilumab.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.